ClinicalTrials.gg
CompletedNCT01216891Updated Nov 3, 2016

Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis

An interventional study of Multi-element, team-oriented treatment in Schizophrenia, Schizoaffective Disorder and Schizophreniform Disorder, sponsored by Research Foundation for Mental Hygiene, Inc.. Completed at 2 sites in United States. Open to participants aged 15 Years to 35 Years. Per ClinicalTrials.gov, last updated 2016-11-03.

Sponsored by Research Foundation for Mental Hygiene, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
15 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,466 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
664th of 1,320
65 · median 66
Started
2010
with 73 others
No phase
480 of 1,466
72 open now
Registered
575th of 1,466
by date

Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 664th largest by enrollment of the 1,320 interventional ones that give a count, is one of 74 that started in 2010, is one of 480 with no phase, and was the 575th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 15 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,466 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

This study will assess the effectiveness of an experimental treatment intervention for adolescents and adults who have experienced their first episode of psychosis during the past two years.

The DUP sub-study will collect pathways to care information that will be used to inform the development and pilot testing of strategies that aim to reduce DUP among individuals experiencing a first episode of psychosis.

Read the detailed description

This study is part of the National Institute of Mental Health's Recovery After an Initial Schizophrenia Episode (RAISE) Project. The RAISE Project seeks to fundamentally change the trajectory and prognosis of schizophrenia through coordinated and aggressive treatment in the earliest stages of illness. This study, the RAISE Connection Program, is one of the two independent research studies that NIMH has funded to conduct the NIMH RAISE Project. The Connection Program is being supported in whole or in part with Federal funds from the American Recovery and Reinvestment Act of 2009 and the NIMH, National Institutes of Health, Department of Health and Human Services. The Connection Program aims to to assess the effectiveness of a Team-based intervention for individuals with a first psychotic episode, observing outcomes over time for our study participants. When tracking outcomes, the Connection Program will make comparisons with what is known about the natural history of untreated first episode of psychosis as well as usual care outcomes from other experimental studies.

This study is for people who have experienced symptoms such as hallucinations, unusual thoughts or beliefs, or disorganized thinking for the first time during the past two years. Without treatment, many people have a difficult time with these symptoms, which can be very upsetting and also make it hard to socialize, study, or work.

People have different wishes and needs, and it is not clear what combination of treatments and services is best for any one person. There are many possible treatments and services, such as medications, talk therapy, case management, and school and job counseling. This study will adapt and evaluate the impact of a comprehensive and integrated treatment intervention for first episode psychosis to be delivered in real-world practice settings to promote symptomatic recovery, minimize disability, and maximize social, academic, and vocational functioning.

Participation in this study will last up to 2 years. At the baseline visit, participants will be enrolled to receive the experimental intervention. During the study period, participants will take part in research interviews every three to six months for a total of 6 interviews. Each of these research interviews will take 1.5 to 3 hours to complete. Assessments of participants' health condition, overall function and illness severity, employment status, academic performance, and social functioning will be conducted during these research interviews. In addition to assessing functioning and illness severity, this study will also address substance abuse and utilization of healthcare services. Participants will also be measured for their height, weight and waist circumference. This portion of the study concluded in December 2013.

The RAISE-DUP contract modification seeks additional information on the referral pathways that resulted in enrollment in the RAISE Connection Program from individuals who participated in RAISE Connection Program services and their family members. Information gathered through qualitative research interviews will be used to inform the development and pilot testing of outreach, education, and engagement intervention strategies, to serve the larger goal of reducing the duration of untreated psychosis among individuals experiencing a first episode of psychosis.

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorder
  • Delusional Disorder
  • Psychosis

Keywords

  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorder
  • Delusional Disorder
  • Psychosis
  • First episode
04

Who can participate

Ages eligible
15 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range: 15-35 years old (16-35 years old in New York)
  • Diagnosis of schizophrenia, schizoaffective and schizophreniform disorder, delusional disorder, or psychosis not otherwise specified (NOS)
  • Duration of psychotic symptoms > 1 week and \< 2 years
  • Ability to provide
  • Ability to speak and understand English
  • Anticipated availability to participate in the intervention for at least 1 year
  • RAISE-DUP: participants must have been enrolled in the RAISE study

Exclusion criteria

Exclusion Criteria:

  • Medical conditions which impair function independent of psychosis
  • Other diagnoses associated with psychosis:
  • Substance-induced psychotic disorder
  • Psychotic affective disorder (major depressive or manic episode with psychotic features)
  • Psychotic disorder due to a general medication condition
  • Mental retardation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Team-based treatment

    Behavioral: Multi-element, team-oriented treatment

Interventions

  • BehavioralMulti-element, team-oriented treatment

    Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.

06

What researchers measure

Primary outcomes

  1. The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)

    This measures occupational functioning, social functioning and symptom severity.

    Time frame: Measured at baseline

  2. The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)

    Time frame: Measured at Month 6

  3. The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)

    Time frame: Measured at Month 12

  4. The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)

    Time frame: Measured at Month 18

  5. The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)

    Time frame: Measured at Month 24

  6. Pathways to Care Qualitative Interview

    This assessment gathers information on help-seeking events and participant recommendations.

    Time frame: Measured at baseline

Secondary outcomes

  1. The Clinical Global Impression (CGI) - Severity scale

    This assesses the level of severity of illness.

    Time frame: Measured at baseline

  2. Calgary Depression Scale

    This assesses depression in people with schizophrenia.

    Time frame: Measured at baseline

  3. Positive and Negative Syndrome Scale for Schizophrenia (PANSS)

    This measures the presence and severity of symptoms of schizophrenia.

    Time frame: Measured at baseline

  4. The Clinical Global Impression (CGI) - Severity scale

    This assesses the level of severity of illness.

    Time frame: Measured at Month 6

  5. The Clinical Global Impression (CGI) - Severity scale

    This assesses the level of severity of illness.

    Time frame: Measured at Month 12

  6. The Clinical Global Impression (CGI) - Severity scale

    This assesses the level of severity of illness.

    Time frame: Measured at Month 18

  7. The Clinical Global Impression (CGI) - Severity scale

    This assesses the level of severity of illness.

    Time frame: Measured at Month 24

  8. Calgary Depression Scale

    This assesses depression in people with schizophrenia.

    Time frame: Measured at Month 6

  9. Calgary Depression Scale

    This assesses depression in people with schizophrenia.

    Time frame: Measured at Month 12

  10. Calgary Depression Scale

    This assesses depression in people with schizophrenia.

    Time frame: Measured at Month 18

  11. Calgary Depression Scale

    This assesses depression in people with schizophrenia.

    Time frame: Measured at Month 24

  12. Positive and Negative Syndrome Scale for Schizophrenia (PANSS)

    This measures the presence and severity of symptoms of schizophrenia.

    Time frame: Measured at Month 6

  13. Positive and Negative Syndrome Scale for Schizophrenia (PANSS)

    This measures the presence and severity of symptoms of schizophrenia.

    Time frame: Measured at Month 12

  14. Positive and Negative Syndrome Scale for Schizophrenia (PANSS)

    This measures the presence and severity of symptoms of schizophrenia.

    Time frame: Measured at Month 18

  15. Positive and Negative Syndrome Scale for Schizophrenia (PANSS)

    This measures the presence and severity of symptoms of schizophrenia.

    Time frame: Measured at Month 24

07

Study locations

2 sites
  • University of Maryland Medical Center, Carruthers Clinic
    Baltimore, Maryland 21230, United States
  • Washington Heights Community Service Clinic
    New York, New York 10032, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Jan 2015 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2010
First posted
Oct 7, 2010
Start
Oct 2010
Primary completionActual
Jan 2015
CompletionActual
Aug 2016
Last update
Nov 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01216891
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Collaborators
National Institute of Mental Health (NIMH), University of Maryland, New York State Office of Mental Health (OMH), Maryland Department of Health and Mental Hygiene
Responsible party
Lisa Dixon (Director Center for Practice Innovations, Research Foundation for Mental Hygiene, Inc.) — Principal investigator
First posted
Oct 7, 2010
Start date
Oct 2010
Primary completion
Jan 2015
Completion
Aug 2016
Last update
Nov 3, 2016

Study contacts

Lisa Dixon, MD
principal investigator · Columbia University
Melanie Bennett, PhD
principal investigator · University of Maryland

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion